Next generation of
heart disease diagnosis
Ensuring that patients worldwide have
access to heart disease diagnosis
and treatment.
Cardio Intelligence Inc.
Philosophy
We support medical practices facing a shortage of cardiologists
by providing AI-based medical device software and cloud services.
Our aim is to build a brighter future by improving access to ECG tests
for arrhythmia patients and assisting them.
MISSION
Providing every patient with the opportunity to receive diagnosis and treatment for heart disease.
VISION
Supporting medical professionals worldwide with technology.
VALUE
Development of medical devices that are truly beneficial in the medical field.
Products
SmartRobin AI Series is a long-term ECG analysis software that automatically detects atrial fibrillation (AF). AF is a major cause of stroke and can be prevented through early diagnosis and treatment.
However, detection of AF is difficult for non-specialists in the field of cardiology, and furthermore, ECG analysis is time-consuming and labor-intensive.
The quick ECG analysis by the SmartRobin AI Series will not only solve problems experienced by medical professionals, but will also contribute to reducing the burden of hospital visits for patients.
*This product is only available in Japan at this time.
Portfolio
In addition to the existing SmartRobin projects, following three pipelines are in progress.
Company History
- 2019
-
June: Acquired Type II Marketing License for Medical Devices. Acquired Medical Device Manufacturer registration.
October: Head office was founded at 35-1, Higashiazabu 2-chome, Minato-ku, Tokyo. - 2020
-
August: Raised 35 million JPY in seed round funding
August: Adopted by the Japan Agency for Medical Research and Development (AMED) as a Research Project for the Promotion of Medical Device Development.
October: Our initiatives introduced to four Asian countries as Japan Healthcare Services as part of the Asian Health Initiative promoted by the Cabinet Secretariat. - 2021
-
February: Raised 140 million JPY in Pre-Series A funding
June: Adopted by the PwC Foundation as a grant recipient for 2021.
September: Started joint development with JSR Corporation, a manufacturer of long-term ECG.
October: Adopted for the Tokyo Metropolitan Government's 13th Subsidy Program to Support the Commercialization of Medical Devices
December: Obtained the First Product (Software as a Medical Device) certification - 2022
-
January: Obtained patent No. 7002168.
April: Launched The long-term ECG analysis software, SmartRobin AI Series
April: Received the "Medtec Grand Prize" at the 10th Medtec Innovation Awards
May: Head office relocated to 1-25-5, Higashiazabu, Minato-ku, Tokyo
June: Obtained license to sell and lend highly controlled medical device
August: Raised 430 million JPY in Series A funding
October: Adopted for the Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project
November: Signed a business alliance agreement with the International University of Health and Welfare for industry- academia collaboration
November: Raised an additional 200 million JPY in Series A funding - 2023
- May: Obtained the ISO 27001 certification, the international ISMS standard.
- 2024
- March: Raised an additional funds
Company Information
Company Name | Cardio Intelligence Inc. |
---|---|
Location | Head office: VORT Azabu East 2F, 1-25-5 Higashi-Azabu, Minato-ku, Tokyo, 106-0044 Google Map |
Established | October, 2019 |
Paid-in Capital | 865.12 million JPY (including capital surplus) |
Representative | Yuichi Tamura, President and CEO |
Officers | CDO Mineki Takechi CTO Tomohiro Takata |
Our Mission |
|
Qualifications | Class II Marketing License for Medical Devices (License No. 13B2X10429), Medical Device Manufacturer (Registration No. 13BZ201666) |